Related Experiment Video
Updated: May 29, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Statin therapy and multiple sclerosis disability in a population-based cohort
M Mateo Paz Soldán1, Sean J Pittock, Stephen D Weigand
1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|September 13, 2011
Summary
Statins did not significantly alter disability progression in multiple sclerosis (MS) patients. This study found no difference in long-term disease course for MS patients receiving statin therapy compared to controls.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) involves axonal damage and inflammatory demyelination.
- Statins may offer neuroprotective and anti-inflammatory benefits, but their impact on MS pathology is debated.
- Existing research presents conflicting evidence regarding statins' effects on MS disease processes.
Purpose of the Study:
- To evaluate the effect of statin therapy on disability progression in patients with multiple sclerosis (MS).
Main Methods:
- Retrospective review of medical records from a population-based MS cohort in Olmsted County, Minnesota.
- Comparison of disability progression between MS patients who received statin therapy and those who did not.
- Analysis of changes in Expanded Disability Status Scale (EDSS) scores over time.
Main Results:
- No significant difference in disability progression was observed between the statin and no-statin groups (p = 0.39).
- Mean absolute change in disability scores was similar: +0.69 (±1.49) for statin users versus +0.61 (±1.31) for non-users.
- The proportion of patients worsening by 1.0 or more on the EDSS was identical (40%) in both groups.
Conclusions:
- Statin therapy, at typical hyperlipidemia doses, did not impact the long-term disability progression in this cohort of multiple sclerosis patients.
- Findings suggest that statins do not alter the clinical course of MS.
- Further research may be needed to explore potential benefits or risks in specific MS subtypes or treatment durations.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.